Edition:
United States

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

5.51USD
20 Apr 2018
Change (% chg)

$-0.12 (-2.13%)
Prev Close
$5.63
Open
$5.62
Day's High
$5.68
Day's Low
$5.50
Volume
762,456
Avg. Vol
1,330,272
52-wk High
$14.15
52-wk Low
$5.28

Chart for

About

Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that... (more)

Overall

Beta: 0.32
Market Cap(Mil.): $1,230.60
Shares Outstanding(Mil.): 223.34
Dividend: --
Yield (%): --

Financials

  ENDP.OQ Industry Sector
P/E (TTM): -- 31.01 33.60
EPS (TTM): -5.69 -- --
ROI: -12.05 13.60 13.19
ROE: -79.64 15.26 15.00

Endo unit settles case ahead of first state court testosterone trial

Endo International's Auxilium unit on Tuesday settled a lawsuit over its testosterone replacement drug, just days before the case was set to go to trial in what would have been the first such legal proceeding at the Philadelphia Court of Common Pleas.

Jan 03 2018

Endo unit cleared of liability in first testosterone replacement trial

NEW YORK A federal jury in Chicago said on Thursday that Endo International's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim.

Nov 16 2017

Endo unit cleared of liability in first testosterone replacement trial

NEW YORK, Nov 16 A federal jury in Chicago said on Thursday that Endo International's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim.

Nov 16 2017

Earnings vs. Estimates